Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. av Hermansen, K, Kolotkin, R, Hammer, M, Zdravkovic, M, Matthews, D

Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEA... av Frid, A, Hermansen, K, Nauck, M, Shah, N, Tankova, T, Mitha, I, Zdravkovic, M, Matthews, D

Greater in vivo than in vitro pulsatility of insulin secretion with synchronized insulin and somatostatin secretory pulses. av Matthews, DR, Hermansen, K, Connolly, A, Gray, D, Schmitz, O, Clark, A, Orskov, H, Turner, R

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)... av Nauck, M, Frid, A, Hermansen, K, Shah, N, Tankova, T, Mitha, I, Zdravkovic, M, Düring, M, Matthews, DR

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study av Nauck, M, Frid, A, Hermansen, K, Thomsen, AB, During, M, Shah, N, Tankova, T, Mitha, I, Matthews, D

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes av Nauck, M, Frid, A, Hermansen, K, Shah, N, Tankova, T, Mitha, I, Zdravkovic, M, Düring, M, Matthews, DR

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. av Nauck, M, Frid, A, Hermansen, K, Thomsen, AB, During, M, Shah, N, Tankova, T, Mitha, I, Matthews, DR

Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin av Hermansen, K, Nauck, M, Frid, A, Shah, N, Tankova, T, Mitha, I, During, M, Zdravkovic, M, Matthews, D

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a... av Jendle, J, Nauck, M, Matthews, DR, Frid, A, Hermansen, K, Düring, M, Zdravkovic, M, Strauss, B, Garber, A

The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visce... av Jendle, J, Nauck, M, Matthews, D, Frid, A, Hermansen, K, During, M, Zdravkovic, M, Strauss, B, Garber, A